Compassionate use of long‐acting cabotegravir plus rilpivirine for people living with HIV ‐1 in need of parenteral antiretroviral therapy

Ronald D'Amico,Santiago Cenoz Gomis, Riya Moodley,Rodica Van Solingen‐Ristea,Bryan Baugh,Erika Van Landuyt,Veerle Van Eygen,Sherene Min,Amy Cutrell,Caroline Foster, Daniella Chilton,Sabine D. Allard, Annemiek Ruiter

HIV Medicine（2022）

引用 10|浏览0

暂无评分

摘要

Most people living with HIV-1 had advanced disease and achieved (16/28) or maintained (6/7) virological suppression with LA therapy. Cabotegravir LA + rilpivirine LA as compassionate use provided a valuable treatment option for individuals with adherence issues with oral therapy and advanced disease.

查看译文

关键词

HIV-1 infection,injectable therapy,integrase strand transfer inhibitor,non-nucleoside reverse transcriptase inhibitor,single patient request

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要